Danaher Corporation vs Dover Corp — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Dover Corp trades at $188.83 (market cap $25.45B). The key difference: Danaher Corporation is far larger — about 6× Dover Corp's market cap, and Dover Corp pays the higher dividend (1.11%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Dover Corp for 73 Days on average.
| DHR | DOV | |
|---|---|---|
Market Cap | $152.87B | $25.45B |
Volume | 5,228,698 | 661,758 |
Sector | Health | Industrials |
52-Week High | $242.05 | $233.31 |
52-Week Low | $161.91 | $161.16 |
Typical Hold Time | 69 Days | 73 Days |
Enterprise Value | $175.08B | $26.95B |
Dividend Yield | 0.74% | 1.11% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Dover Corporation (DOV) trades at $188.83, up 0.29% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $2.74 exceeding expectations, supported by robust profitability margins including 39.58% gross margin and 13.48% net income margin. Recent acquisitions and product launches demonstrate ongoing business expansion.
Analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential. Key risks include technical weakness and cyclical industrial exposure, but strong cash flow generation and dividend history provide stability. The combination of earnings momentum and institutional support suggests long-term value despite near-term technical headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →